FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037153533> ?p ?o ?g. }

• W2037153533 endingPage "198" @default.
• W2037153533 startingPage "186" @default.
• W2037153533 abstract "Background Despite many available therapies, patients with type 2 diabetes mellitus (T2DM) frequently do not achieve/maintain glycaemic control. Furthermore, side effects such as hypoglycaemia and weight gain may limit therapy choices. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces hyperglycaemia by increasing glucosuria independently of insulin, representing a novel approach in T2DM. Dapagliflozin efficacy, safety and tolerability were evaluated across a wide range of clinical trials. Methods Dapagliflozin 10-mg efficacy data from (i) two short-term, active-comparator studies (vs. metformin-XR over 24 weeks and vs. glipizide over 52 weeks), (ii) pooled 24-week analyses of five placebo-controlled trials (as monotherapy or add-on therapy), and (iii) long-term studies over 2 years; dapagliflozin 5- and 10-mg pooled safety data from 12 placebo-controlled trials; and cardiovascular safety and malignancy data from 19 dapagliflozin studies were evaluated. Results In treatment-naïve patients (baseline HbA1c 9%), dapagliflozin reduced HbA1c (−1.45%) similarly to metformin-XR (−1.44%). In metformin-treated patients (baseline HbA1c 7.7%), dapagliflozin achieved a clinically significant reduction (−0.52%) similar to glipizide (−0.52%). In pooled 24-week analyses, dapagliflozin vs. placebo differences in HbA1c, weight and systolic blood pressure (SBP) were −0.60%, −1.61 kg and −3.6 mmHg, respectively. At 2 years, dapagliflozin vs. placebo differences in HbA1c and weight were −0.44 to −0.80% and −2.41 to −3.19 kg, respectively, and vs. glipizide, differences in HbA1c, weight, and SBP were −0.18%, −5.06 kg, and −3.89 mmHg, respectively. Major hypoglycaemia with dapagliflozin was rare (< 0.1%). Urinary tract and genital infections were more common with dapagliflozin, but responded to standard care and rarely led to study discontinuation. Events of renal failure/impairment and malignancies were rare and balanced across treatment groups. Pooled analyses did not indicate that dapagliflozin increased cardiovascular event risk. Conclusions Dapagliflozin improved glycaemic control, decreased body weight, and lowered blood pressure across the spectrum of T2DM disease, with maintenance of these benefits over time." @default.
• W2037153533 created "2016-06-24" @default.
• W2037153533 creator A5009695940 @default.
• W2037153533 creator A5047195042 @default.
• W2037153533 creator A5050249929 @default.
• W2037153533 creator A5076877188 @default.
• W2037153533 date "2014-11-28" @default.
• W2037153533 modified "2023-09-27" @default.
• W2037153533 title "Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time" @default.
• W2037153533 cites W1523363225 @default.
• W2037153533 cites W1669146696 @default.
• W2037153533 cites W1953840628 @default.
• W2037153533 cites W1973240292 @default.
• W2037153533 cites W2000047428 @default.
• W2037153533 cites W2008443217 @default.
• W2037153533 cites W2015157047 @default.
• W2037153533 cites W2021524336 @default.
• W2037153533 cites W2026609170 @default.
• W2037153533 cites W2027686692 @default.
• W2037153533 cites W2059147055 @default.
• W2037153533 cites W2065946881 @default.
• W2037153533 cites W2072040765 @default.
• W2037153533 cites W2077519024 @default.
• W2037153533 cites W2081510795 @default.
• W2037153533 cites W2109728760 @default.
• W2037153533 cites W2114031829 @default.
• W2037153533 cites W2114276479 @default.
• W2037153533 cites W2117505171 @default.
• W2037153533 cites W2122077393 @default.
• W2037153533 cites W2123984464 @default.
• W2037153533 cites W2128050336 @default.
• W2037153533 cites W2148958160 @default.
• W2037153533 cites W2149973065 @default.
• W2037153533 cites W2151402544 @default.
• W2037153533 cites W2157586798 @default.
• W2037153533 cites W2162037642 @default.
• W2037153533 cites W2162427196 @default.
• W2037153533 cites W2163691729 @default.
• W2037153533 cites W2167245776 @default.
• W2037153533 cites W2171049608 @default.
• W2037153533 cites W2171183320 @default.
• W2037153533 cites W2171786511 @default.
• W2037153533 cites W2172193326 @default.
• W2037153533 cites W4214766071 @default.
• W2037153533 doi "https://doi.org/10.1111/ijcp.12531" @default.
• W2037153533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25438821" @default.
• W2037153533 hasPublicationYear "2014" @default.
• W2037153533 type Work @default.
• W2037153533 sameAs 2037153533 @default.
• W2037153533 citedByCount "13" @default.
• W2037153533 countsByYear W20371535332015 @default.
• W2037153533 countsByYear W20371535332016 @default.
• W2037153533 countsByYear W20371535332017 @default.
• W2037153533 countsByYear W20371535332018 @default.
• W2037153533 countsByYear W20371535332019 @default.
• W2037153533 countsByYear W20371535332021 @default.
• W2037153533 crossrefType "journal-article" @default.
• W2037153533 hasAuthorship W2037153533A5009695940 @default.
• W2037153533 hasAuthorship W2037153533A5047195042 @default.
• W2037153533 hasAuthorship W2037153533A5050249929 @default.
• W2037153533 hasAuthorship W2037153533A5076877188 @default.
• W2037153533 hasConcept C126322002 @default.
• W2037153533 hasConcept C126894567 @default.
• W2037153533 hasConcept C134018914 @default.
• W2037153533 hasConcept C142724271 @default.
• W2037153533 hasConcept C197934379 @default.
• W2037153533 hasConcept C204787440 @default.
• W2037153533 hasConcept C27081682 @default.
• W2037153533 hasConcept C2777180221 @default.
• W2037153533 hasConcept C2777422806 @default.
• W2037153533 hasConcept C2778375690 @default.
• W2037153533 hasConcept C2779306644 @default.
• W2037153533 hasConcept C2779555806 @default.
• W2037153533 hasConcept C2780323712 @default.
• W2037153533 hasConcept C2780473172 @default.
• W2037153533 hasConcept C511355011 @default.
• W2037153533 hasConcept C544821477 @default.
• W2037153533 hasConcept C555293320 @default.
• W2037153533 hasConcept C71924100 @default.
• W2037153533 hasConceptScore W2037153533C126322002 @default.
• W2037153533 hasConceptScore W2037153533C126894567 @default.
• W2037153533 hasConceptScore W2037153533C134018914 @default.
• W2037153533 hasConceptScore W2037153533C142724271 @default.
• W2037153533 hasConceptScore W2037153533C197934379 @default.
• W2037153533 hasConceptScore W2037153533C204787440 @default.
• W2037153533 hasConceptScore W2037153533C27081682 @default.
• W2037153533 hasConceptScore W2037153533C2777180221 @default.
• W2037153533 hasConceptScore W2037153533C2777422806 @default.
• W2037153533 hasConceptScore W2037153533C2778375690 @default.
• W2037153533 hasConceptScore W2037153533C2779306644 @default.
• W2037153533 hasConceptScore W2037153533C2779555806 @default.
• W2037153533 hasConceptScore W2037153533C2780323712 @default.
• W2037153533 hasConceptScore W2037153533C2780473172 @default.
• W2037153533 hasConceptScore W2037153533C511355011 @default.
• W2037153533 hasConceptScore W2037153533C544821477 @default.
• W2037153533 hasConceptScore W2037153533C555293320 @default.
• W2037153533 hasConceptScore W2037153533C71924100 @default.
• W2037153533 hasIssue "2" @default.

• next